Company Description
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States.
The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.
It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease.
SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Eric Schlorff |
Contact Details
Address: 3513 Brighton Boulevard, Suite 410 Denver, Colorado 80216 United States | |
| Phone | 844 427 8100 |
| Website | seastarmedical.com |
Stock Details
| Ticker Symbol | ICU |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001831868 |
| CUSIP Number | 81256L104 |
| ISIN Number | US81256L1044 |
| Employer ID | 85-3681132 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Eric Schlorff | Chief Executive Officer, President and Executive Director |
| David A. Green CPA, M.B.A. | Chief Financial Officer |
| Colonel Kevin Chung FACP, M.D. | Chief Medical Officer |
| Dr. H. David Humes M.D. | Co-Founder and Managing Director |
| Tom Mullen | Vice President of Operations and Product Development |
| Tim Varacek | Senior Vice President of Commercial and Business Operations |
| Sai P. Iyer Ph.D. | Senior Vice President of Medical Affairs and Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 6, 2025 | DEF 14A | Other definitive proxy statements |
| May 6, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | EFFECT | Notice of Effectiveness |
| Apr 25, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 25, 2025 | 8-K | Current Report |
| Apr 23, 2025 | 10-K/A | [Amend] Annual report |
| Apr 22, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 22, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 2, 2025 | 424B5 | Filing |
| Mar 28, 2025 | 8-K | Current Report |